@genetic-counselor
Genetic Counselor
Forum Replies Created
-
Posts
-
Yes. However, it is important to distinguish between inherited genetic changes and acquired genetic changes.
The DNA sequence inherited from your parents is generally stable throughout your life. These inherited variants are called germline variants and are present in the reproductive cells and generally throughout the body’s cells.
However, as we age, individual cells can acquire additional DNA changes. These are called somatic mutations.Somatic mutations may occur because of:
– Errors during normal DNA replication.
– Natural cellular ageing.
– Exposure to ultraviolet radiation.
– Tobacco smoke and certain environmental chemicals.
– Defects in DNA repair mechanisms.For example, cancer develops when cells accumulate genetic and other molecular alterations that disrupt normal growth and cell division.
An important distinction is that germline variants can potentially be transmitted to the next generation, whereas somatic mutations are generally restricted to the affected cell lineage and are not inherited by children.There are several biological mechanisms that explain why a genetic condition may remain undetected for years.
1. Progressive accumulation of cellular damage
Some genetic conditions cause gradual damage to cells, tissues or organs. The effects may initially be too small to produce noticeable symptoms. As damage accumulates, the individual may eventually develop clinical manifestations.
2. Age-dependent gene expression
Certain genes play important roles during specific stages of life. A genetic alteration may have little noticeable effect during childhood but become clinically significant during adulthood.
3. Incomplete penetrance
Penetrance refers to the proportion of individuals carrying a particular genetic variant who actually develop the associated condition.
For example, two individuals may carry the same pathogenic variant, but one may develop the disease while the other remains asymptomatic throughout life.
4. The second-hit mechanism
Some genetic conditions, particularly certain cancers, require more than one genetic event.
For example, in hereditary retinoblastoma, an individual may inherit one altered copy of the RB1 gene. A second acquired alteration in the remaining functional copy can lead to tumour development.
Absolutely! Some genetic conditions have an adult-onset presentation. This means an individual may carry a disease-associated genetic variant for many years without experiencing symptoms.
Here are some important examples:
1. Huntington’s disease
Huntington’s disease is an autosomal dominant neurodegenerative disorder caused by a CAG repeat expansion in the HTT gene.
Although the genetic alteration is present from conception, symptoms commonly develop between 30 and 50 years of age. These may include involuntary movements, behavioural changes, cognitive decline and progressive neurological dysfunction.
2. Hereditary breast and ovarian cancer syndrome
Pathogenic variants in the BRCA1 and BRCA2 genes increase the risk of developing breast, ovarian and certain other cancers.
Individuals carrying these variants are generally healthy at birth. However, their cancer risk increases during adulthood.
3. Inherited cardiomyopathies
Conditions such as hypertrophic cardiomyopathy can result from pathogenic variants in genes involved in cardiac muscle structure, including MYH7 and MYBPC3.
Some individuals develop symptoms during childhood, while others remain asymptomatic until adulthood.
4. Familial Alzheimer’s disease
Rare inherited forms of Alzheimer’s disease can result from pathogenic variants in genes such as APP, PSEN1 and PSEN2. Depending on the genetic alteration, symptoms may develop during adulthood, sometimes much earlier than in typical late-onset Alzheimer’s disease.
Although these terms are frequently used together, they have different meanings.
Genetic conditions are disorders caused by changes in DNA. These changes may be inherited from parents or arise spontaneously during the formation of reproductive cells or early embryonic development.
Genetic conditions can result from:
– Single-gene mutations.
– Chromosomal abnormalities.
– Changes in chromosome number or structure.
– Mitochondrial DNA variants.
– Complex interactions between multiple genes.
Congenital conditions, on the other hand, refer to abnormalities or conditions that are present at birth, regardless of their underlying cause.Congenital conditions may result from:
– Genetic abnormalities.
– Maternal infections during pregnancy.
– Exposure to certain medications or harmful substances.
– Nutritional deficiencies.
– Other environmental or developmental factors.Examples:
– Down syndrome is a genetic and congenital condition caused by an additional copy of chromosome 21 in most cases.
– Congenital heart defects may have genetic, environmental or multifactorial causes.
– Some inherited neurological disorders are genetic but do not become symptomatic until adulthood.
The important distinction is that genetic describes the underlying cause, whereas congenital describes when the condition is present.No. Not all genetic conditions are noticeable at birth.
When a person inherits a disease-associated genetic variant from either parent, that genetic change is generally present from conception. However, the presence of a genetic variant does not necessarily mean that the individual will immediately develop symptoms.
The age at which a genetic condition becomes clinically apparent is called the age of onset. Depending on the condition, symptoms may develop:
– Before birth: Some genetic conditions can affect fetal growth and development and may be detected during pregnancy.
– At birth: Certain genetic disorders present with noticeable physical features, structural abnormalities or metabolic problems.
– During childhood: Some conditions become apparent when developmental milestones are delayed or specific symptoms emerge.
– During adolescence: Hormonal changes, growth and developmental processes may reveal certain inherited conditions.
– During adulthood: Some genetic disorders remain undetected until the individual reaches their 20s, 30s, 40s or even later.– Never: Some individuals carry a disease-associated genetic variant but never develop the associated condition because of incomplete penetrance.
For example, a person carrying a pathogenic variant associated with hereditary breast cancer may be completely healthy during childhood and adolescence but have an increased risk of developing cancer during adulthood.Yes. Genetic variations can influence INR levels and warfarin dose requirements. However, fluctuating INR values are not necessarily caused by genetic factors. Understanding the distinction between inherited drug sensitivity and acquired changes in anticoagulation is important for effective patient management.
The CYP2C9 and VKORC1 genes are the principal pharmacogenetic contributors to warfarin response. Variants in CYP2C9 can reduce the activity of the enzyme responsible for metabolising S-warfarin. This may prolong drug exposure, increase anticoagulant effects, and cause INR to rise at a given dose. Variants in VKORC1 can alter the expression of vitamin K epoxide reductase, the target of warfarin. Individuals with increased sensitivity may achieve a higher INR at lower doses than individuals with lower sensitivity.
These genetic differences are especially relevant when treatment is initiated because they help explain why patients may require substantially different starting doses. However, inherited genetic variants generally remain constant throughout life. Consequently, they are more likely to explain baseline dose requirements and sensitivity than sudden fluctuations in INR in a patient whose anticoagulation was previously stable.
Common causes of INR instability should therefore be investigated first. Changes in dietary vitamin K intake, missed or inconsistent doses, newly prescribed medications, discontinuation of interacting drugs, alcohol consumption, acute infections, diarrhoea, vomiting, and liver dysfunction can all affect warfarin response. Certain antibiotics and antifungal agents, for example, can increase INR, although the direction and magnitude of an interaction depend on the specific medication and clinical circumstances.
When INR fluctuates repeatedly despite consistent medication use, stable dietary habits, and appropriate management of interacting drugs and illnesses, pharmacogenetic testing may be considered in selected patients. Testing can help clarify inherited sensitivity, particularly if the initial dose requirement was unusual or excessive anticoagulation occurred early in treatment. However, testing is not routinely required for every patient with an unstable INR.
Management involves reviewing adherence, medications, diet, illness, and other clinical factors, followed by appropriate INR testing and dose adjustment. Patients should not independently change their warfarin dose.
In conclusion, CYP2C9 and VKORC1 variants can influence warfarin sensitivity and dosing requirements. Nevertheless, genetic variation is only one contributor to anticoagulation variability. Identifying reversible causes of INR instability and maintaining regular INR monitoring remain essential to prevent both thrombosis and serious bleeding complications.
Yes. Genetic variations can influence INR levels and warfarin dose requirements. However, fluctuating INR values are not necessarily caused by genetic factors. Understanding the distinction between inherited drug sensitivity and acquired changes in anticoagulation is important for effective patient management.
The CYP2C9 and VKORC1 genes are the principal pharmacogenetic contributors to warfarin response. Variants in CYP2C9 can reduce the activity of the enzyme responsible for metabolising S-warfarin. This may prolong drug exposure, increase anticoagulant effects, and cause INR to rise at a given dose. Variants in VKORC1 can alter the expression of vitamin K epoxide reductase, the target of warfarin. Individuals with increased sensitivity may achieve a higher INR at lower doses than individuals with lower sensitivity.
These genetic differences are especially relevant when treatment is initiated because they help explain why patients may require substantially different starting doses. However, inherited genetic variants generally remain constant throughout life. Consequently, they are more likely to explain baseline dose requirements and sensitivity than sudden fluctuations in INR in a patient whose anticoagulation was previously stable.
Common causes of INR instability should therefore be investigated first. Changes in dietary vitamin K intake, missed or inconsistent doses, newly prescribed medications, discontinuation of interacting drugs, alcohol consumption, acute infections, diarrhoea, vomiting, and liver dysfunction can all affect warfarin response. Certain antibiotics and antifungal agents, for example, can increase INR, although the direction and magnitude of an interaction depend on the specific medication and clinical circumstances.
When INR fluctuates repeatedly despite consistent medication use, stable dietary habits, and appropriate management of interacting drugs and illnesses, pharmacogenetic testing may be considered in selected patients. Testing can help clarify inherited sensitivity, particularly if the initial dose requirement was unusual or excessive anticoagulation occurred early in treatment. However, testing is not routinely required for every patient with an unstable INR.
Management involves reviewing adherence, medications, diet, illness, and other clinical factors, followed by appropriate INR testing and dose adjustment. Patients should not independently change their warfarin dose.
In conclusion, CYP2C9 and VKORC1 variants can influence warfarin sensitivity and dosing requirements. Nevertheless, genetic variation is only one contributor to anticoagulation variability. Identifying reversible causes of INR instability and maintaining regular INR monitoring remain essential to prevent both thrombosis and serious bleeding complications.
Warfarin and Acitrom (acenocoumarol) are oral anticoagulants belonging to the vitamin K antagonist (VKA) class. Both are used to prevent or treat thromboembolic conditions, including deep vein thrombosis (DVT), pulmonary embolism (PE), and selected cases of atrial fibrillation and mechanical heart valve replacement. Although they act through the same biological pathway, their pharmacological properties and dosing characteristics differ.
Warfarin and acenocoumarol inhibit vitamin K epoxide reductase, an enzyme encoded by the VKORC1 gene. Inhibition of this enzyme reduces the regeneration of active vitamin K, thereby decreasing the production of functional vitamin K-dependent clotting factors II, VII, IX, and X. This reduces the blood’s ability to form clots.
Genetic variations in VKORC1 and CYP2C9 can influence responses to both medications. The VKORC1 gene affects sensitivity to vitamin K antagonists, while CYP2C9 encodes an enzyme involved in their metabolism. Reduced-function CYP2C9 variants can slow the clearance of these drugs and increase the risk of excessive anticoagulation. However, the magnitude of these effects can differ between warfarin and acenocoumarol because their pharmacokinetic properties are not identical.
Pharmacogenetic testing may therefore provide useful information when estimating an initial acenocoumarol dose, particularly in patients with relevant genetic variants. Studies in different populations, including Indian populations, have investigated associations between these variants and acenocoumarol dose requirements. Nevertheless, the strength of the evidence and the clinical usefulness of specific dosing algorithms vary across populations and treatment settings.
An important distinction is that international pharmacogenetic dosing recommendations and algorithms are more extensively established for warfarin. They should not automatically be applied to acenocoumarol without considering drug-specific evidence, local guidance, and the patient’s clinical characteristics.
As with warfarin, acenocoumarol dosing is influenced by age, liver function, dietary vitamin K intake, interacting medications, illness, and adherence. Regular INR monitoring is essential to assess anticoagulant response and guide dose adjustments.
In conclusion, CYP2C9 and VKORC1 testing may help explain individual differences in both warfarin and Acitrom dosing. However, genetic results should be interpreted using medication-specific evidence rather than assuming that identical dosing recommendations apply to both drugs. For either medication, genetic testing supports dose selection but does not replace INR-guided clinical management.
Warfarin dosing differs significantly between patients because individuals vary in their genetic makeup, drug metabolism, sensitivity to anticoagulation, and clinical characteristics. Even when two patients have the same diagnosis and take the same medication, they may require different doses to achieve the same therapeutic International Normalized Ratio (INR).
Two important genes explain part of this variability: CYP2C9 and VKORC1.
The CYP2C9 gene encodes a liver enzyme responsible for metabolising S-warfarin, the more potent enantiomer of the drug. Certain variants, particularly CYP2C9 *2 and *3, reduce enzyme activity. Individuals carrying these variants may eliminate warfarin more slowly and therefore require lower doses to avoid excessive anticoagulation and bleeding.
The VKORC1 gene encodes vitamin K epoxide reductase, the molecular target of warfarin. This enzyme helps recycle vitamin K, which is required for the production of functional clotting factors II, VII, IX, and X. Genetic variations affecting VKORC1 expression can change sensitivity to warfarin. Some patients require substantially lower doses because their clotting system is more sensitive to the drug, whereas others require higher doses.
However, genetics is only one part of the explanation. Age is important because older adults often require lower doses and may have a higher bleeding risk. Body size, liver function, nutritional status, and vitamin K intake also influence dose requirements. Foods rich in vitamin K, such as spinach, kale, and other leafy green vegetables, can reduce warfarin’s anticoagulant effect when intake changes substantially.
Drug interactions are another major factor. Certain antibiotics, antifungals, anti-inflammatory medicines, and other medications can alter warfarin response or bleeding risk. Acute illness, alcohol intake, poor adherence, and changes in general health may further affect anticoagulation control.
Pharmacogenetic testing can identify relevant variants in CYP2C9 and VKORC1 and combine these findings with clinical information to estimate an appropriate initial dose. Nevertheless, the patient’s response must be assessed using INR monitoring.
In conclusion, differences in warfarin dosing arise from the combined effects of genetic variation, physiological characteristics, diet, medications, and environmental factors. Pharmacogenomics helps explain inherited differences in drug response and supports personalised treatment, but no single gene or genetic test can independently determine the exact warfarin dose for every patient.
Yes. Regular International Normalized Ratio (INR) monitoring remains essential even after pharmacogenetic testing for warfarin dosing. Genetic testing helps predict how an individual may respond to warfarin, but it cannot replace laboratory monitoring of anticoagulation. INR measures the time taken for blood to clot relative to a standardised reference and helps clinicians determine whether anticoagulation is within the desired therapeutic range.
Warfarin acts by inhibiting vitamin K epoxide reductase, an enzyme encoded by the VKORC1 gene. This reduces the production of functional vitamin K-dependent clotting factors, including factors II, VII, IX, and X. The CYP2C9 gene influences the metabolism and clearance of warfarin. Variations in these genes can affect the dose required to achieve a therapeutic INR.
Although genetic testing provides valuable information about inherited differences in drug response, it cannot account for all factors that influence INR. Changes in dietary vitamin K intake, the introduction or discontinuation of interacting medications, alcohol consumption, acute illness, liver dysfunction, and changes in general health can alter warfarin’s effect. Antibiotics, for example, may increase INR in some patients, while certain other medications may reduce anticoagulant effectiveness. Missed doses or inconsistent medication timing can also affect anticoagulation control.
INR monitoring allows clinicians to detect these changes and adjust the dose when necessary. The target INR depends on the clinical indication; many patients receiving warfarin for atrial fibrillation or venous thromboembolism have a target range of 2.0–3.0, whereas selected patients with mechanical heart valves may require a different target. Monitoring frequency depends on treatment stability, clinical circumstances, and local protocols. Testing is generally more frequent when warfarin is first initiated, after dose changes, or when interacting medications or illnesses occur.
Failure to monitor INR can lead to serious complications. A low INR may indicate inadequate anticoagulation and an increased risk of thrombosis, while a high INR may increase the risk of bleeding, including potentially life-threatening haemorrhage.
In conclusion, pharmacogenetic testing involving CYP2C9 and VKORC1 can support initial warfarin dose selection, but it does not eliminate the need for INR monitoring. Genetic testing predicts drug response; INR monitoring measures the patient’s actual anticoagulant effect. Both clinical assessment and laboratory monitoring are necessary for safe, effective, long-term warfarin therapy.
Warfarin is an oral anticoagulant used to prevent and treat blood clots in conditions such as deep vein thrombosis (DVT), pulmonary embolism (PE), and atrial fibrillation. It is also used in patients with certain mechanical heart valves. Although warfarin is effective, the appropriate dose varies considerably between individuals. Pharmacogenetic testing can help predict a patient’s initial warfarin dose by identifying genetic variations that influence drug metabolism and sensitivity.
Two major genes involved in warfarin dosing are CYP2C9 and VKORC1. The CYP2C9 gene encodes an enzyme responsible for metabolising the more potent S-warfarin enantiomer. Certain variants, including CYP2C9 *2 and *3, reduce enzyme activity, resulting in slower drug clearance and an increased risk of excessive anticoagulation and bleeding. The VKORC1 gene encodes vitamin K epoxide reductase, the target of warfarin. Variants in its regulatory region can alter gene expression and influence how sensitive a patient is to warfarin. Patients with certain VKORC1 variants may require lower doses, whereas others may require higher doses.
Additional factors, including age, body weight, liver function, dietary vitamin K intake, interacting medications, smoking status, and clinical indication, also influence dose requirements. Therefore, genetic information is often combined with clinical variables in validated warfarin-dosing algorithms to estimate an appropriate starting dose.
Pharmacogenetic testing may be particularly useful when initiating therapy in selected patients, especially when genetic results are available before treatment begins. It can help clinicians avoid excessive initial dosing in genetically sensitive individuals and potentially reduce the risk of adverse events. However, the clinical benefit varies according to the patient population, availability of genetic results, and quality of anticoagulation management.
Importantly, genetic testing cannot determine the exact dose required by every patient. It provides an estimate or starting-dose recommendation rather than a permanent prescription. The final dose must be individualised according to the patient’s response, measured through regular International Normalized Ratio (INR) testing.
Whether a child will inherit hereditary ataxia depends on the specific genetic variant responsible for the condition and its inheritance pattern. Different types of ataxia follow different inheritance patterns, so an individual’s risk cannot be calculated accurately without understanding the underlying diagnosis.
Autosomal dominant inheritance is common in several spinocerebellar ataxias, including SCA1, SCA2, SCA3 and SCA12. In these conditions, a disease-associated variant in one copy of the relevant gene can cause the disorder. If a parent carries the causative variant, each child generally has a 50% chance of inheriting it. This probability is independent for each pregnancy. A child who does not inherit the familial variant will generally not develop that particular inherited disorder through that variant.
Autosomal recessive inheritance applies to conditions such as Friedreich ataxia and ataxia with vitamin E deficiency. In these disorders, an affected individual usually has disease-causing variants in both copies of the relevant gene. If both parents are carriers of pathogenic variants in the same gene, each pregnancy has a 25% chance of producing an affected child, a 50% chance of producing a carrier child and a 25% chance of producing a child who inherits neither familial variant. If an affected person has children with someone who is not a carrier, their children are generally expected to be carriers, assuming the partner has no relevant pathogenic variant.
Some rare neurological conditions follow X-linked or mitochondrial inheritance, which involves different risk calculations.
A family history is helpful but not always conclusive. Hereditary ataxia can appear to skip generations because of reduced penetrance, late symptom onset, unrecognised symptoms or new genetic variants. Therefore, the absence of affected relatives does not completely exclude a genetic cause.
Genetic counselling is recommended before predictive or reproductive testing. A genetic counsellor can review the family history, explain the genetic result, assess the risk to children and discuss options such as prenatal diagnosis or preimplantation genetic testing where appropriate and available.
Testing should ideally begin with an affected family member to identify the causative variant. Once the familial variant is established, targeted testing may be offered to relatives after informed consent.
Life expectancy in hereditary ataxia varies considerably. It depends on the specific genetic condition, age at symptom onset, rate of disease progression, associated medical complications and the individual’s overall health. Therefore, it is not possible to give one life expectancy estimate that applies to everyone with hereditary ataxia.
Some spinocerebellar ataxias progress slowly, and affected individuals may live for decades after their symptoms begin. Others progress more rapidly or cause additional neurological problems that influence independence and long-term health. Even people with the same genetic diagnosis can experience different disease courses because of differences in genetic background, repeat length in certain disorders and other modifying factors.
Friedreich ataxia illustrates why the underlying diagnosis matters. In addition to balance and coordination difficulties, it may affect the heart, causing cardiomyopathy or heart rhythm abnormalities. Diabetes can also occur in some affected individuals. These complications can substantially influence long-term outcomes, making regular cardiac assessment and appropriate medical management important.
Some hereditary ataxias primarily affect coordination and walking, while others may involve speech, swallowing, sensation, eye movements or additional neurological functions. Swallowing difficulties can increase the risk of aspiration and respiratory infections. Falls and reduced mobility can also lead to injuries and complications.
Early diagnosis and appropriate follow-up can help manage these risks. Depending on the genetic type, care may involve a neurologist, physiotherapist, speech and language therapist, cardiologist, dietitian and other specialists. Monitoring should be tailored to the expected complications of the particular condition rather than following the same schedule for every patient.
Genetic testing can help establish the specific diagnosis, while clinical examinations and follow-up assessments provide information about the person’s current condition and rate of progression. However, genetic results cannot always predict an exact age of onset, severity or life expectancy.
Patients and families should discuss prognosis with a specialist familiar with the relevant genetic condition. This discussion should consider the individual’s symptoms, medical history, genetic findings and available treatments. Emotional support and genetic counselling can also help families plan for future care.
Most hereditary ataxias do not currently have a definitive cure that reverses the underlying genetic change and completely restores normal neurological function. However, treatment options are available to manage symptoms, address complications, preserve independence and improve quality of life. Importantly, some inherited ataxias have specific treatments that can slow or prevent further neurological damage.
One example is ataxia with vitamin E deficiency (AVED), caused by pathogenic variants in the TTPA gene. These variants interfere with vitamin E transport and can lead to progressive neurological symptoms. Vitamin E supplementation under medical supervision can prevent progression and may improve some symptoms, particularly when treatment starts early. This makes early diagnosis particularly important.
Friedreich ataxia is another inherited neurological disorder. Omaveloxolone is an approved treatment for eligible patients in certain countries, including the United States. Clinical trials have shown benefits in neurological function measures, although the medication is not a cure and does not eliminate the underlying genetic variant. Approval, availability and eligibility vary by country, age and clinical circumstances.
For many spinocerebellar ataxias, treatment focuses on symptom management and rehabilitation. Physiotherapy can help maintain balance, strength and mobility. Occupational therapy can support everyday activities, while speech and language therapy may help with communication and swallowing difficulties. Assistive devices, such as walking aids, can reduce falls and improve independence.
Doctors may also monitor for associated complications, including muscle stiffness, neuropathy, vision problems, swallowing difficulties and heart disease where relevant. Genetic counselling helps patients and families understand the diagnosis, inheritance pattern and reproductive implications.
Research into hereditary ataxia is progressing. Investigational approaches include gene-based therapies, RNA-targeted treatments and other strategies intended to modify disease mechanisms. However, experimental therapies should not be considered established cures unless supported by appropriate evidence and regulatory approval.
Treatment plans should be tailored to the specific genetic condition, symptoms and individual health needs. Patients should avoid taking high-dose vitamins or other supplements without medical advice, as unnecessary supplementation can cause harm.
India has a diverse population with considerable genetic variation between regions and communities. Several hereditary ataxias have been reported in Indian patients, including spinocerebellar ataxia type 12 (SCA12), spinocerebellar ataxia type 2 (SCA2), SCA1, SCA3 and Friedreich ataxia. The relative frequency of these conditions varies across studies and populations, so one type cannot be assumed to be the most common throughout the entire country.
SCA12 is an important hereditary ataxia reported in India, particularly in certain families from northern India. It is associated with a CAG repeat expansion in the PPP2R2B gene. Symptoms can include progressive tremor, difficulty with balance, impaired coordination and changes in walking. The age at onset and severity can differ considerably between affected individuals.
SCA2 is another frequently identified type. It results from a CAG repeat expansion in the ATXN2 gene. People may experience progressive gait instability, limb incoordination, slowed eye movements and, in some cases, other neurological features. SCA2 is inherited in an autosomal dominant pattern, meaning that an affected individual with a disease-causing variant generally has a 50% chance of passing it to each child.
SCA1 and SCA3 are also important causes of inherited cerebellar degeneration. Friedreich ataxia differs from the common dominant SCAs because it is generally inherited in an autosomal recessive pattern and is associated with pathogenic variants affecting the FXN gene. It may involve the heart, sensory nerves and other systems in addition to coordination difficulties.
The most frequently diagnosed type depends on the geographical area, family history, clinical referral patterns and the genetic tests used. Some studies have focused on particular communities or specialist centres and therefore may not represent the entire Indian population.
Diagnosis requires appropriate genetic testing. Repeat-expansion disorders such as SCA1, SCA2, SCA3 and SCA12 often require dedicated repeat-expansion testing because routine exome sequencing may not reliably identify the relevant expansions.
